Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution.

Lakota EA, Sato N, Koresawa T, Kondo K, Bhavnani SM, Ambrose PG, Rubino CM.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00267-19. doi: 10.1128/AAC.00267-19. Print 2019 Aug.

2.

Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned.

Younis IR, Lakota EA, Volpe DA, Patel V, Xu Y, Sahajwalla CG.

J Clin Pharmacol. 2019 Aug;59(8):1035-1043. doi: 10.1002/jcph.1405. Epub 2019 Apr 11. Review.

PMID:
30973652
3.

Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.

Bader JC, Lakota EA, Dale GE, Sader HS, Rex JH, Ambrose PG, Bhavnani SM.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00318-19. doi: 10.1128/AAC.00318-19. Print 2019 Jun.

4.

Erratum for Lakota et al., "Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data".

Lakota EA, Ong V, Flanagan S, Rubino CM.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e00333-19. doi: 10.1128/AAC.00333-19. Print 2019 Apr. No abstract available.

5.

Time for Precision: A World Without Susceptibility Breakpoints.

Bader JC, Lakota EA, Andes DR, Rubino CM, Ambrose PG, Bhavnani SM.

Open Forum Infect Dis. 2018 Oct 31;5(12):ofy282. doi: 10.1093/ofid/ofy282. eCollection 2018 Dec.

6.

Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes.

Lakota EA, Landersdorfer CB, Zhang L, Nafziger AN, Bertino JS Jr, Bhavnani SM, Forrest A.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00784-18. doi: 10.1128/AAC.00784-18. Print 2018 Oct.

7.

Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.

Lakota EA, Landersdorfer CB, Nation RL, Li J, Kaye KS, Rao GG, Forrest A.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00483-18. doi: 10.1128/AAC.00483-18. Print 2018 Jul.

8.

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.

Bader JC, Lakota EA, Flanagan S, Ong V, Sandison T, Rubino CM, Bhavnani SM, Ambrose PG.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02614-17. doi: 10.1128/AAC.02614-17. Print 2018 Jun.

9.

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data.

Lakota EA, Ong V, Flanagan S, Rubino CM.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02603-17. doi: 10.1128/AAC.02603-17. Print 2018 Jun. Erratum in: Antimicrob Agents Chemother. 2019 Mar 27;63(4):.

10.

Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs.

Lakota EA, Bader JC, Rubino CM.

Curr Opin Pharmacol. 2017 Oct;36:139-145. doi: 10.1016/j.coph.2017.10.014. Epub 2017 Nov 20. Review.

PMID:
29156443
11.

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.

Lakota EA, Bader JC, Ong V, Bartizal K, Miesel L, Andes DR, Bhavnani SM, Rubino CM, Ambrose PG, Lepak AJ.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00758-17. doi: 10.1128/AAC.00758-17. Print 2017 Nov.

12.

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.

Bulik CC, Okusanya ÓO, Lakota EA, Forrest A, Bhavnani SM, Hoover JL, Andes DR, Ambrose PG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e00115-16. doi: 10.1128/AAC.00115-16. Print 2017 Feb.

Supplemental Content

Loading ...
Support Center